Cytokine induction of VCAM-1 but not IL13R?2 on glioma cells: a tale of two antibodies.

ABSTRACT: The interleukin-13 receptor alpha2 (IL13R?2) is a cell surface receptor that is over-expressed by a subset of high-grade gliomas, but not expressed at significant levels by normal brain tissue. For both malignant and non-malignant cells, IL13R?2 surface expression is reported to be induced by various cytokines such as IL-4 or IL-13 and tumor necrosis factor (TNF). Our group has developed a therapeutic platform to target IL13R?2-positive brain tumors by engineering human cytotoxic T lymphocytes (CTLs) to express the IL13-zetakine chimeric antigen receptor. We therefore sought to investigate the potential of cytokine stimulation to induce IL13R?2 cell surface expression, and thereby increase susceptibility to IL13R?2-specific T cell killing. In the course of these experiments, we unexpectedly found that the commercially available putative IL13R?2-specific monoclonal antibody B-D13 recognizes cytokine-induced VCAM-1 on glioblastoma. We provide evidence that the induced receptor is not IL13R?2, because its expression does not consistently correlate with IL13R?2 mRNA levels, it does not bind IL-13, and it is not recognized by IL13-zetakine CTL. Instead we demonstrate by immunoprecipitation experiments and mass spectrometry that the antigen recognized by the B-D13 antibody following cytokine stimulation is VCAM-1, and that VCAM-1, but not IL13R?2, is induced on glioma cells by TNF alone or in combination with IL-13 or IL-4. Further evaluation of several commercial B-D13 antibodies revealed that B-D13 is bi-specific, recognizing both IL13R?2 and VCAM-1. This binding is non-overlapping based on soluble receptor competition experiments, and mass spectrometry identifies two distinct heavy and light chain species, providing evidence that the B-D13 reagent is di-clonal. PE-conjugation of the B-D13 antibody appears to disrupt IL13R?2 recognition, while maintaining VCAM-1 specificity. While this work calls into question previous studies that have used the B-D13 antibody to assess IL13R?2 expression, it also suggests that TNF may have significant effects on glioma biology by up-regulating VCAM-1.

SUBMITTER: Mahadev V 

PROVIDER: S-EPMC4008428 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature